A multi-center Phase III study was discussed at the 2009 meeting of the American Urological Association.

[1] The perliminar results of this study has demonstrated that the risk for incurring bone fractures in men on androgen deprivation therapy (ADT) is reduced when the drug toremifene (Acapodene) is administered.

Men, fighting advanced prostate cancer, often receive long-t